The polymorphism of GSTM1, mutagen sensitivity in colon cancer and healthy control.
The aim of this article is to study the relationship between GSTM1 polymorphism and colon cancer and to compare the chromosomal breakage induced by mutagen in a colon cancer group and healthy controls. Using PCR to identify the GSTM1 genotype, we found the frequency of GSTM1- in colon cancer (n = 19) and control group (n = 23) was 36.8% and 26.1%, respectively (p > 0.05, chi 2-test). The bleomycin-induced chromosomal breakage (break/cell) in the patient group was 0.75 +/- 0.29, and in the control group 0.42 +/- (0.24) (p < 0.05, t-test). The percentage of mutagen sensitivity (b/c > 0.8) in the patient group (68%) was 4 times as high as that in the control group (20%). The mutagen hypersensitivity (b/c > 1.0) in the patient group (47%) was 5 times as high as that in the control group (12%). The odds radio was 6.6.
Guo
J Y
JY
Research Unit of Genotoxicology, School of Public Health, Sun-Yat-Sen University of Medical Sciences, Guangzhou, China.
Wan
D S
DS
Zeng
R P
RP
Zhang
Q
Q
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001761:Bleomycin / Q000494:pharmacology; D002681:China; D002869:Chromosome Aberrations; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics*; D004249:DNA Damage / Q000187:drug effects / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D017353:Gene Deletion; D005787:Gene Frequency; D005982:Glutathione Transferase / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009153:Mutagens / Q000494:pharmacology*; D011110:Polymorphism, Genetic
D000903:Antibiotics, Antineoplastic; D009153:Mutagens; D001761:Bleomycin; D005982:Glutathione Transferase